Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms
- 浏览0
The Journal of Immunology
4823-4832页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



